Moleculin reports 37% blinded remission rate in AML trial interim data
Go back to Moleculin reports 37% blinded remission rate in AML trial interim data| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.79 +0.08 (11.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.71 | 52 Week High | $9.58 | |||
| Open | $0.74 | 52 Week Low | $2.34 | |||
| Day High | $0.80 | P/E | N/A | |||
| Day Low | $0.72 | EPS | $-0.34 | |||
| Volume | 485,518 | |||||
